Virtonomy has closed a Series A financing round of more than five million euros. Companisto is the lead investor, and Bayern Kapital supports the company with a renewed and increased commitment. Founded in 2019, the Munich-based startup develops a cloud-based platform that allows medical device manufacturers to test their innovations on virtual patients.
The digital patient twins are based on realistic datasets and multiphysical simulations. Companies conduct tests faster, more frequently, and in different iterations. Virtonomy reduces the development time for medical devices by up to 40 percent and lowers costs in the millions. In addition to individual tests, the platform enables population analyses and complete virtual studies.
With the fresh capital, Virtonomy is advancing the next growth phase. The company plans to further scale the platform internationally, achieve regulatory validation for integrating virtual studies into actual approval procedures, and expand its global presence and team. CEO Simon Sonntag puts the significance of the financing into perspective:
“The Series A financing round enables us to implement the next level of scaling: deeper regulatory integration, greater geographic reach, and more powerful infrastructure for digital clinical testing.”
Focus on scaling and regulation
Bayern Kapital has been accompanying Virtonomy since the seed financing round in 2021. The investment is centered on the goal of reducing animal and human testing as part of clinical studies. According to the investors, the platform addresses a bottleneck in medical device technology: the high complexity and costs of traditional clinical studies.
Companisto also sees great potential. Investment Manager Robin Ghosh says:
“Virtonomy combines a clear technological advantage with an internationally scalable model. The potential impact on MedTech development is substantial, and we see strong momentum for the next phase.”
Monika Steger, managing director of Bayern Kapital, adds:
“Virtonomy removes a central bottleneck in medical device technology. The ability to reduce complexity, costs, and the need for physical studies positions the company to expand strongly worldwide.”
Currently, internationally leading MedTech companies such as Medtronic, Johnson & Johnson, and Boston Scientific already use the platform. This positions Virtonomy as a relevant player in the digital transformation of clinical studies, extending well beyond the Munich location.
